Sam Tsimikas, MD

For those interested in the Saturday Morning Lp(a) Class, the course is now linked to my bio and is open access. Big thanks to @TheBhupiThakur for organizing the twittorials. It is ~500 tweets in 24 classes. Syllabus enclosed. I wish to all the joy of learning.

Yes, BHDx is closing, so the licensees will look for alternatives. There is also a new high sensitivity method that benchmarks to our @UCSD Elisa.

Thanks, going back to NEJM 2005 and JACC 2014, we showed OxPL (and Lp(a), but OxPL was more potent and independent predictor) CVD risk is conditioned on highly pro-inflammatory IL-1 haplotype. I hope now some of the companies that have these data can now analyze this and test it in large studies to assess if this combo, OxPL/Lp(a)/IL-1, picks up the highest risk patents.

Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels.

1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients.
2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly.
3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering.
4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se.
5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent.
6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason.
7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future.
8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a).

I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field.

And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies,

I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future.

With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future.

Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.

Wonderful presentation by @AJLeikas @UCSDCardiology post doc cardiologist on oxidized phospholipid carriers (@OxPL_apoB) and refractory angina, with simultaneous publication in @JACCJournals. Should we measure OxPL and is it a target of therapy for these "no further option" patients? sciencedirect.com/science/articl…. .